BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Health Hope Pharma and Hanmi Grant Gilead Global Rights to Encequidar in Virology

Health Hope Pharma Limited announced that it has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. ("Gilead") for ence...

September 30, 2025 | News

Daiichi Sankyo and AstraZeneca’s ENHERTU delivers second positive phase 3 win in HER2 positive early breast cancer

Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become...

September 30, 2025 | News

AbbVie Submits FDA Application for Tavapadon After Positive Phase 3 TEMPO Results in Parkinson’s Disease

Submission supported by data from the Phase 3 TEMPO program that demonstrated symptomatic improvement across the Parkinson's disease spectrum Positive r...

September 29, 2025 | News

ASCP Launches Performance and Diagnostics Insights to Elevate Laboratory Benchmarking and Patient Care

- The American Society for Clinical Pathology (ASCP) has launched Performance and Diagnostics Insights (PDI), a groundbreaking platform designed to transfo...

September 29, 2025 | News

GCCL and Frontage Laboratories Sign Strategic MOU to Strengthen Global Clinical Trial Capabilities

GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, and Frontage Laboratories, Inc., a US...

September 25, 2025 | News

Lunit and CellCarta Form Global Partnership to Advance AI-Powered Pathology in Clinical Trials

Lunit , a leading provider of AI for cancer diagnostics and biomarkers for oncology therapeutics, announced a strategic partnership with CellCarta, a globa...

September 25, 2025 | News

Akeso Doses First Patient in Phase II Study of Novel TIGIT/TGF-β Bifunctional Antibody for Pancreatic Cancer

Akeso Inc. has announced that the first patient has been dosed in its registrational Phase II study (AK130-202), evaluating AK130, a fully independent...

September 23, 2025 | News

Galux Validates AI-Driven Platform with Atomic-Level Precision in De Novo Antibody Design

Study confirms the novelty and atomic-level precision of de novo antibody design, including cryo-EM validation on a designed anti-PD-L1 antibody Finding...

September 23, 2025 | News

Sanofi and Regeneron Receive CHMP Recommendation for Dupixent in Chronic Spontaneous Urticaria in EU

Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo ...

September 23, 2025 | News

CorestemChemon Phase 3 ALSummit Trial Shows Subgroup Benefit of Neuronata-R® in ALS

CorestemChemon Inc. announced that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel) an autolo...

September 22, 2025 | News

Ono Pharmaceutical Wins EU Approval for Vimseltinib as First TGCT Therapy

Vimseltinib is the first and only therapy with marketing authorization for the treatment of TGCT in the European Union Ono Pharmaceutical Co., a...

September 19, 2025 | News

Mabwell and Aditum Bio Launch Kalexo Bio with $1 Billion siRNA Deal for Dyslipidemia and ASCVD

Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) and Aditum Bio announced the launch of Kalexo Bio, a new company formed in conjunction with an exc...

September 18, 2025 | News

Skyhawk’s SKY-0515 Shows 62% Reduction in Mutant Huntingtin at Day 84 in Huntington’s Disease Trial

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose Additional finding...

September 18, 2025 | News

Johnson & Johnson’s Amivantamab–Lazertinib Combo Extends Survival Beyond Four Years in Asia NSCLC Cohort

Median overall survival in Asia cohort is projected to exceed four years, demonstrating a durable benefit and surpassing osimertinib monotherapy by more th...

September 17, 2025 | News

Stay Connected